Meeting
2018 ASCO Annual Meeting
NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Authors
Anita Ahmed Turk
University of Wisconsin Carbone Cancer Center, Madison, WI
Anita Ahmed Turk , Ticiana A.B. Leal , Nancy Chan , Robert Wesolowski , Ruth O'Regan , Mark E. Burkard , Amye Tevaarwerk , Laurel Rice , Toby Christopher Campbell , Justine Yang Bruce , Jyoti Malhotra , Lisa Marie Barroilhet , Janice M. Mehnert , Jens C. Eickhoff , Glenn Liu , Kari Braun Wisinski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02317874
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2548)
DOI
10.1200/JCO.2018.36.15_suppl.2548
Abstract #
2548
Poster Bd #
374
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2016 ASCO Annual Meeting
A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors.
First Author: Fangfei Gao
Poster
2013 ASCO Annual Meeting
Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.
First Author: Katherine M. Bell-McGuinn
Poster
2012 ASCO Annual Meeting
ABT-888 (veliparib) in combination with weekly carboplatin and paclitaxel in advanced solid tumors.
First Author: Jorge Arturo Rios-Perez